Total Payments
$13,998
2024 Payments
$5,026
Companies
28
Transactions
238
Medicare Patients
9,850
Medicare Billing
$515,919
Payment Breakdown by Category
Food & Beverage$6,208 (44.4%)
Travel$4,023 (28.7%)
Consulting$1,874 (13.4%)
Other$1,800 (12.9%)
Education$92.93 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,208 | 221 | 44.4% |
| Travel and Lodging | $4,023 | 13 | 28.7% |
| Consulting Fee | $1,874 | 1 | 13.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,800 | 1 | 12.9% |
| Education | $92.93 | 2 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $3,931 | 41 | $0 (2024) |
| Biosense Webster, Inc. | $3,491 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,973 | 7 | $0 (2023) |
| Medtronic Vascular, Inc. | $1,301 | 13 | $0 (2020) |
| Medtronic, Inc. | $644.15 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $491.48 | 31 | $0 (2024) |
| PFIZER INC. | $393.67 | 34 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $240.19 | 19 | $0 (2024) |
| CVRx, Inc. | $232.11 | 2 | $0 (2022) |
| Amgen Inc. | $210.60 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,026 | 46 | Biosense Webster, Inc. ($2,780) |
| 2023 | $1,778 | 40 | Medtronic, Inc. ($524.32) |
| 2022 | $637.21 | 13 | CVRx, Inc. ($232.11) |
| 2021 | $71.93 | 4 | Amgen Inc. ($55.78) |
| 2020 | $131.01 | 7 | Novartis Pharmaceuticals Corporation ($45.45) |
| 2019 | $481.78 | 20 | Biosense Webster, Inc. ($155.68) |
| 2018 | $1,903 | 49 | Medtronic Vascular, Inc. ($1,215) |
| 2017 | $3,969 | 59 | E.R. Squibb & Sons, L.L.C. ($1,922) |
All Payment Transactions
238 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $122.75 | General |
| 12/16/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $11.36 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/19/2024 | CARDIVA MEDICAL, INC. | OPTOWIRE (Device) | Food and Beverage | In-kind items and services | $37.69 | General |
| Category: DEVICES | ||||||
| 09/17/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $102.50 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 09/10/2024 | Biosense Webster, Inc. | CARTO 3 (Device) | Consulting Fee | Cash or cash equivalent | $1,874.25 | General |
| Category: Cardiology | ||||||
| 09/10/2024 | Biosense Webster, Inc. | CARTO 3 (Device) | Travel and Lodging | Cash or cash equivalent | $750.75 | General |
| Category: Cardiology | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/05/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $58.82 | General |
| 08/28/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/20/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/19/2024 | Teleflex LLC | GUIDELINER (Device) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: INTERVENTIONAL ACCESS | ||||||
| 08/12/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $70.14 | General |
| Category: General - Therapies_CRM | ||||||
| 08/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Obesity | ||||||
| 08/02/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $58.82 | General |
| Category: Cardiology | ||||||
| 07/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/19/2024 | Biosense Webster, Inc. | — | Food and Beverage | In-kind items and services | $28.77 | General |
| 07/15/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/19/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Obesity | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/07/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $11.40 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/26/2024 | Boston Scientific Corporation | — | Travel and Lodging | In-kind items and services | $324.37 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 2,859 | 3,822 | $445,771 | $153,701 |
| 2022 | 31 | 2,646 | 3,363 | $351,991 | $120,036 |
| 2021 | 30 | 2,390 | 3,157 | $429,428 | $142,947 |
| 2020 | 34 | 1,955 | 2,368 | $282,336 | $99,234 |
Total Patients
9,850
Total Services
12,710
Medicare Billing
$515,919
Procedure Codes
132
All Medicare Procedures & Services
132 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93656 | Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | Facility | 2023 | 32 | 33 | $53,922 | $24,373 | 45.2% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 106 | 284 | $33,512 | $16,298 | 48.6% |
| 33208 | Insertion of pacemaker and upper and lower heart chamber electrode | Facility | 2023 | 30 | 30 | $50,670 | $12,233 | 24.1% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 525 | 762 | $36,576 | $10,896 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 112 | 126 | $23,562 | $10,397 | 44.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 146 | 167 | $21,042 | $10,273 | 48.8% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 351 | 491 | $33,879 | $9,986 | 29.5% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 169 | 249 | $33,864 | $6,004 | 17.7% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 106 | 284 | $15,620 | $5,149 | 33.0% |
| 33225 | Insertion of left lower heart electrode for pacemaker or defibrillator | Facility | 2023 | 14 | 14 | $20,748 | $5,124 | 24.7% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 157 | 172 | $13,272 | $5,037 | 37.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 59 | 59 | $11,151 | $4,680 | 42.0% |
| 33228 | Removal and replacement of dual lead permanent pacemaker | Facility | 2023 | 16 | 16 | $11,664 | $4,214 | 36.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 319 | 390 | $16,770 | $3,889 | 23.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $10,185 | $3,862 | 37.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 33 | 34 | $8,330 | $3,441 | 41.3% |
| 93655 | Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | Facility | 2023 | 11 | 12 | $7,344 | $2,911 | 39.6% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 125 | 128 | $5,760 | $2,176 | 37.8% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 92 | 92 | $4,784 | $1,830 | 38.3% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 28 | 28 | $5,460 | $1,803 | 33.0% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 36 | 38 | $4,873 | $1,779 | 36.5% |
| 93283 | Programming of dual lead implantable defibrillator system | Office | 2023 | 26 | 28 | $2,779 | $1,120 | 40.3% |
| 93281 | Programming of multiple lead pacemaker system | Office | 2023 | 26 | 29 | $2,784 | $1,044 | 37.5% |
| 93225 | Electrocardiogram (ecg) 2-day continuous | Office | 2023 | 67 | 70 | $3,780 | $913.02 | 24.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 15 | $2,745 | $871.78 | 31.8% |
About Dr. Christopher Frank, MD
Dr. Christopher Frank, MD is a Clinical Cardiac Electrophysiology healthcare provider based in Gahanna, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2008. The National Provider Identifier (NPI) number assigned to this provider is 1699942474.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Frank, MD has received a total of $13,998 in payments from pharmaceutical and medical device companies, with $5,026 received in 2024. These payments were reported across 238 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($6,208).
As a Medicare-enrolled provider, Frank has provided services to 9,850 Medicare beneficiaries, totaling 12,710 services with total Medicare billing of $515,919. Data is available for 4 years (2020–2023), covering 132 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Cardiac Electrophysiology
- Location Gahanna, OH
- Active Since 05/12/2008
- Last Updated 01/25/2022
- Taxonomy Code 207RC0001X
- Entity Type Individual
- NPI Number 1699942474
Products in Payments
- CARTO 3 (Device) $3,274
- ELIQUIS (Drug) $2,178
- GENERAL - THERAPIES (Device) $1,355
- SelectSecure (Device) $1,164
- ENTRESTO (Drug) $357.05
- SELECTSECURE (Device) $274.20
- XARELTO (Drug) $240.19
- Barostim Neo System (Device) $232.11
- WATCHMAN FLX (Device) $231.76
- Carto 3 System (Device) $183.36
- Assure WCD (Device) $163.80
- LifeVest (Device) $150.79
- General - Therapies (Device) $137.66
- LEQVIO (Drug) $134.43
- Repatha (Biological) $131.85
- CHANTIX (Drug) $129.54
- COREVALVE EVOLUT R (Device) $119.83
- EMBLEM (Device) $107.97
- ENDOTAK (Device) $102.23
- Confirm Rx (Device) $85.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.